IL1RN and prostate carcinoma: Supporting this hypothesis, in an earlier study we once compared the mRNA levels of the IL1RN before ADT (pre-ADT) and after ADT (post-ADT, 22 weeks after ADT) in seven prostate cancer patients [23].